Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007549.pdf
0001415889-24-007549.rtf
0001415889-24-007549.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007554.pdf
0001415889-24-007554.rtf
0001415889-24-007554.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007552.pdf
0001415889-24-007552.rtf
0001415889-24-007552.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007557.pdf
0001415889-24-007557.rtf
0001415889-24-007557.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007558.pdf
0001415889-24-007558.rtf
0001415889-24-007558.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007556.pdf
0001415889-24-007556.rtf
0001415889-24-007556.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007559.pdf
0001415889-24-007559.rtf
0001415889-24-007559.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007560.pdf
0001415889-24-007560.rtf
0001415889-24-007560.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007561.pdf
0001415889-24-007561.rtf
0001415889-24-007561.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-007562.pdf
0001415889-24-007562.rtf
0001415889-24-007562.xls